Soleno Therapeutics (SLNO) FCF Margin (2015 - 2026)
Soleno Therapeutics (SLNO) reported FCF Margin of 27.42% for Q1 2026, down 48.3% quarter-over-quarter from 53.03% in Q4 2025.
Soleno Therapeutics (SLNO) FCF Margin (2015 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has 5 years of FCF Margin data on file, last reported at 27.42% in Q1 2026.
- FCF Margin for Q1 2026 came in at 27.42%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 36.99% (changed N/A YoY), and the FY2025 annual result was 24.54%, changed N/A from the prior year.
- FCF Margin retreated to 27.42% in Q1 2026 per SLNO's latest filing, from 53.03% in the prior quarter.
- Over five years, FCF Margin peaked at 65.88% in Q3 2025 and troughed at 38.77% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn | 27.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.42% |
| Dec 31, 2025 | 53.03% |
| Sep 30, 2025 | 65.88% |
| Jun 30, 2025 | -38.77% |
| Jun 30, 2017 | -125,600.00% |
| Mar 31, 2017 | -825.28% |
| Dec 31, 2016 | -89.43% |
| Sep 30, 2016 | 627.66% |
| Jun 30, 2016 | -202,000.00% |
| Mar 31, 2016 | -895.53% |
| Dec 31, 2015 | -4,240.04% |
| Sep 30, 2015 | -10,040.74% |
| Jun 30, 2015 | -2,783.51% |
| Mar 31, 2015 | -8,227.27% |